CAMBRIDGE, Mass., Dec. 2, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in the following conferences in December:
- Piper Jaffray 25th Annual Healthcare Conference at the New York Palace Hotel in New York on Tuesday, December 3 at 1:00 p.m. ET. A live webcast will be available at this link or by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.
- 55th Annual Meeting of the American Society of Hematology (ASH) at the Ernest N. Morial Convention Center in New Orleans, Louisiana December 7-10. Information on the specific presentations, including times and locations, is available here: http://www.epizyme.com/wpcontent/uploads/2013/11/Epizyme-ASH-2013-Curtain-Raiser-Release-.pdf.
- ASH 2013 R&D Presentation on Monday, December 9 at 12:00 p.m. CT. Epizyme and physician investigators will present on current clinical programs and planned 2014 expansion. A live webcast will be available under "Upcoming Events" in the Investor Center section of the Company's website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the presentation.
About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.
SOURCE Epizyme, Inc.